Elacestrant With Targeted Agents May Overcome ET Resistance in Breast Cancer
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Related Articles
Polygenic risk scores and prostate cancer
Research by Fred Hutch Cancer Center genetic epidemiologist Burcu Darst, PhD, and scientists from the Canary Prostate Active Surveillance Study (PASS), suggests that a patient’s…
Plenary lecture emphasizes interrelated factors behind disparities in breast cancer research, care – SABCS Meeting News
Melissa B. Davis, PhD, on Thursday addressed the challenges of unraveling social versus biological drivers of racial disparities in cancer outcomes.
AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals
Overview for AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals
Responses to immune checkpoint inhibitor therapy in NF1 mutated cutaneous melanoma.
We present data on radiographic responses to ICI therapy in advanced melanoma patients with tumors harboring NF1 (Neurofibromatosis 1) mutations.
Consolidation Durvalumab Improves PFS in Unresectable Stage III NSCLC Without Progression After CRT
The PACIFIC-5 study has met its primary end point of improved PFS with consolidation durvalumab after CRT in select unresectable stage III NSCLC.
Vagus nerve stimulation relieves severe depression | WashU Medicine
Results of major clinical trial may pave the way to health insurance coverage for treatment-resistant cases
Tissue factor promotes TREX1 protein stability to evade cGAS-STING innate immune response in pancreatic ductal adenocarcinoma
Oncogene – Tissue factor promotes TREX1 protein stability to evade cGAS-STING innate immune response in pancreatic ductal adenocarcinoma
Role of GLP-1 agonists in breast cancer survivorship setting
Neil Iyengar, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the potential use of GLP-1 or GLP agonist and incretin mimetics during…
The WHO’s 5th classification for AML: expanding the number of genetically defined categories
Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides insight into the 5th iteration of the World Health Organization’s (WHO)…
Biomarkers and Treatment Strategies in CAR T-Cell Therapy for R/R Multiple Myeloma
Doris K. Hansen, MD, discussed a comprehensive analysis of pretreatment biomarkers associated with outcomes in patients receiving idecabtagene vicleucel therapy
